MELBOURNE, Australia — The use of IDegLira, a fixed-ratio combination of the glucagonlike peptide (GLP)-1 receptor agonist liraglutide (Victoza, Novo Nordisk) and insulin degludec (Tresiba, Novo ...

SAN FRANCISCO — In patients with newly diagnosed type 1 diabetes, once-daily liraglutide 1.8 mg as an adjunct to insulin therapy preserved postprandial insulin secretion and reduced insulin dose ...

Patients with schizophrenia are at high risk of developing diabetes, particularly due to the effects of antipsychotic medications, but the results of a recently published trial indicate liraglutide ...

The FDA's approval of the glucagon-like peptide receptor agonist marks the first non-insulin drug approved for youth with type 2 diabetes since the approval of metformin for pediatric use in 2000.

LOS ANGELES (KABC) -- Many people taking a popular diabetes medication have been experiencing weight loss as one of the side effects. Low blood sugar levels brought 59-year-old Anda Lam to her ...

Key market opportunities for liraglutide and semaglutide include their growing role in diabetes and obesity treatment due to ...

SAN FRANCISCO —The glucagon-like peptide-1 (GLP-1) agonist liraglutide (Victoza, Novo Nordisk) taken every day preserved postprandial insulin secretion for 1 year after type 1 diabetes diagnosis in ...

The head-to-head comparison of four classes of medications assessed multiple metabolic, cardiovascular (CV), and safety outcomes for sulfonylurea glimepiride (Amaryl), the DPP-4 inhibitor sitagliptin ...

New post hoc data from the LEADER trial should reassure prescribing physicians that liraglutide (Victoza; Novo Nordisk) is safe in patients with type 2 diabetes with or without a history of NYHA class ...

In a Naples clinic, an unexpected link between a diabetes medication and relief from migraines has caused a stir in the medical community. Researchers at discovered that the diabetes and ...

In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration Monday ...

Insulin glargine and the GLP-1 receptor agonist liraglutide are more effective at achieving an HbA1c of less than 7% than the sulfonylurea glimepiride or the DPP-IV inhibitor sitagliptin, according to ...